Pharmaceutical Juno-B (02126) rose more than 9% in early trading. As of press release, it rose 5.61% to HK$3.01, with a turnover of HK$4,2191,000.
The Zhitong Finance app learned that Pharmaceuticals Juno-B (02126) rose more than 9% in early trading. As of press release, it rose 5.61% to HK$3.01, with a turnover of HK$4,2191,000.
On November 8, according to information from the official website of the State Drug Administration, Heyuan Biotech's new drug marketing application (NDA) for the CAR-T product nakiolensis injection was officially approved, making it the first CAR-T product approved for marketing in China to treat acute leukemia. Up to now, 4 CAR-T products have been approved for marketing in China, including Medicinal Orencet injection (CD19) from Medicinal Juno.
Furthermore, the 2023 health insurance negotiations will begin in November. It is reported that Rickie Orense of Pharmacist will participate in health insurance negotiations. Guangdong Development Securities previously pointed out that since the launch of Reggie Orencet injection in September 2021, production costs have been continuously reduced, and the inclusion of commercial insurance and local supplementary medical plans has gradually increased. This has led to an increase in both 2023H1 billing and infusion, an increase in operating income of 32.93%, and an increase in gross margin to 51.07%.